Medtronic adds trio of spinal Infuse indications; Boston Sci data better on lower back pain;

@FierceMedDev: Bloomberg: Embattled Theranos CEO continues to beat the 'transparency' drum. More | Follow @FierceMedDev

@EmilyWFierce: Novian Health reveals positive study results for breast cancer laser ablation device. Article | Follow @EmilyWFierce

> Medtronic ($MDT) has added a trio of newly approved spinal surgery indications for its Infuse Bone Graft, which is made of a manufactured version of protein rhBMP-2 that exists in the human body to promote bone growth and is applied to an absorbable collagen sponge. Infuse is FDA-approved certain spine, oral-maxillofacial and orthopedic trauma surgeries. More

> Boston Scientific ($BSX) has disclosed data for its Precision Spectra Spinal Cord Stimulator (SCS) showing that it provides 70% more lower back pain relief than with the previous generation Precision Plus SCS System. More

> Consumer health device player iHealth has partnered with diabetic digital health company mySugr to integrate its Logbook diabetes app with the iHealth Wireless Gluco Smart-Monitoring System. mySugr's Logbook already has more than half a million diabetic users. More

Biotech News

@FierceBiotech: AstraZeneca bets on the future of the 'secretome,' joining a $100M research effort. Story | Follow @FierceBiotech

@JohnCFierce: If @woodfordfunds didn't know about the questions circulating around $NWBO, you have to wonder if the DC vax thing came up for review. | Follow @JohnCFierce

@DamianFierce: A lot of culturally embarrassing quotes in this, but reporters calling 5% "an obscure black movement" is as damning as anything Shkreli says. | Follow @DamianFierce

> Wellcome invests $38M in another gene therapy startup, targeting hemophilia. News

> Otonomy wins FDA approval for a first-of-its-kind ear treatment. Article

Pharma News

@FiercePharma: NICE backs Astellas' Xtandi in pre-chemo patients, but J&J's Zytiga isn't so lucky. More | Follow @FiercePharma

@EricPFierce: #Sun #Pharma to launch generic Gleevec Feb. 1 but has said it won't be #manufacturing it at troubled Halol plant. Story | Follow @EricPFierce

@CarlyHFierce: Horizon shells out $510 million for access to gout med Kyrstexxa. News | Follow @CarlyHFierce

> Discount sways U.K. cost gatekeeper on AstraZeneca's ovarian cancer med Lynparza. More

> Sanofi's and Regeneron's Praluent wins top billing on UnitedHealth Group's formulary. Article

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.